The company's CEO sees Tetrault's extensive experience, especially in global human capital strategy and business operations, as a valuable addition to support the evolution of the company.
Sequencing errors and subsequent audit could sway product development path and trigger a shift of ongoing studies to a new CRO, possibly impacting the company's financial health and milestones despite strong cash position.
Insiders remain bullish about the company, implied by the purchase made by the Independent Director even at prices higher than current rate. This suggests a reasonable alignment between the company leadership and shareholder interests.
CEO Dr. Lin expressed confidence in Patricia Turney's appointment, banking on her extensive expertise for ACELYRIN's growth phase. Turney is excited to contribute towards maintaining high-quality standards.
diamonds : 请问，ENDPQ重组后，持有的股票还能有效吗？